摘要
目的对BIM缺失多态性对EGFR突变型NSCLC治疗效果影响的个体患者数据的系统回顾和荟萃分析。方法选取2012年10月—2021年3月间有BIM检测结果患者42例。估计无进展生存期(PFS)的风险比(HRs)。结果Cox风险回归模型发现BIM基因多态性对中位PFS的影响有统计学意义(P=0.046);在单变量分析和多变量Cox回归分析中,BIM缺失都是降低PFS的显著风险因素。结论BIM缺失是EGFR-TKIs治疗的NSCLC患者的PFS显著预测因子。
Objective To conduct a systematic review and meta-analysis of individual patient data and the overall data in the literature database of this research center.Methods There were 42 patients with BIM detection results from October 2012 to March 2021.The hazard ratio(HRs)of PFS was estimated.Results Cox risk regression model found that BIM gene polymorphism had a statistically significant effect on median PPS(P=0.046).BIM deficiency was a significant risk factor for PFS reduction in both univariate and multivariate Cox regression analyses.Conclusion BIM deficiency was a significant predictor of PFS in EGFR-TKIs treated NSCLC patients.
作者
周莉
周俊
李海洋
沈继敏
ZHOU Li;ZHOU Jun;LI Haiyang;SHEN Jimin(Anhui Tongling The Fifth People&apos's Hospital Inner Second Department Anhui,Tongling 244100;Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine Respiratory and Critical Care Medicine Department,Shanghai 200025)
出处
《智慧健康》
2023年第29期34-37,共4页
Smart Healthcare
关键词
BIM
多态性
酪氨酸激酶抑制剂
肺癌
耐药性
BIM
Polymorphism
Tyrosine kinase inhibitors
Lung cancer
Drug resistance
